This study is currently not recruiting participants.

Evaluation of Tenofovir and Emtricitabine Dosing Nomograms and Efficacy in Thrice-Weekly Hemodialysis

Study on Blood Levels of Investigational Medication in Hemodialysis Patients

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to make sure that the blood levels of tenofovir and/or emtricitabine are at a good level in patients receiving hemodialysis three times a week.

Detailed description of study

The purpose of this study is to make sure that the blood levels of tenofovir and/or emtricitabine are at a good level in patients receiving hemodialysis three times a week.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: End Stage Kidney Disease
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the blood levels of investigational medication in patients who are receiving hemodialysis three times a week. Hemodialysis is a process where a machine helps to clean the blood when the kidneys are not working well.

Participants will have their blood tested to measure the levels of the investigational medication. This helps to ensure that the medication is at a safe and effective level in their bodies.

  • Who can participate: The study is open to patients aged 18 and older who are currently receiving hemodialysis three times a week. Additional eligibility criteria may apply.
  • Study details: Participants will engage in specific activities related to the study, distinct from regular blood tests already mentioned.
Updated on 19 Feb 2024. Study ID: 1203008320

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team